Meningococcal Conjugate Vaccine Market - Industry Analysis, Market Size, Share, Trends, Growth and Forecast 2020 - 2025

Report Code: HCR 89641 Report Format: PDF + Excel (Delivery in 48 Hrs)
Meningococcal Conjugate Vaccine Market size is forecast to reach $1.83 billion by 2025, growing at a CAGR of 4.12% during the forecast period 2020-2025. Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria. Rising government awareness programs and increasing government interventions are the major factors driving the growth of the market. Low manufacturing cost and increasing healthcare spending is set to further enhance the overall market demand of meningococcal conjugate vaccine during the forecast period 2020-2025. 

Report Coverage
The report: “Meningococcal Conjugate Vaccine Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Meningococcal Conjugate Vaccine Market. 

By Composition: Mono Vaccine, Combination Vaccine
By Brand: Menactra, Menveo, Neisvac-C, Nimenrix
By End User: Child, Preteen or Teen, Adult
By Geography: North America, Europe, Asia-Pacific, Rest of the World (RoW)

Key Takeaways
  • North America dominated the Meningococcal Conjugate Vaccine Market in 2019 owing to the growing use of meningococcal vaccines for immunization. The Meningococcal Conjugate Vaccine Market scope for different regions will be provided in the final report.
  • Enhanced access to Meningococcal Vaccines in underpenetrated regions and highly unpredictable circulation of meningococcal bacteria is likely to aid in the market growth of Meningococcal Conjugate Vaccine.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Meningococcal Conjugate Vaccine Market report.
  • Lack of awareness of the harmful effect of meningitis on toddlers and young children is poised to create hurdles for the Meningococcal Conjugate Vaccine Market.

Composition - Segment Analysis
Meningococcal vaccination is used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in high risk adults. Vaccines can be monovalent or polyvalent. A monovalent vaccine contains a single strain of a single antigen. Combination vaccines are used to prevent different diseases or that protect against multiple strains of infectious agents causing the same disease. Combination vaccines can be useful to overcome logistic constraints of multiple injections and accommodate for a children’s fear of needles and pain. The development of combination vaccines for protection against multiple diseases began with the combination of individual diphtheria, tetanus, and pertussis vaccines into a single product and this combined vaccine was first used to vaccinate infants and children.

Brand- Segment Analysis
Vaccines can help prevent meningococcal disease which is used to prevent illness caused by Neisseria meningtidiss which are Menactra and   Menveo. Menactra (meningococcal conjugate vaccine) is used to prevent infection caused by meningococcal bacteria.Menactra works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes the body to develop immunity   to the disease. Meningococcal disease is a serious infection caused by a bacterium. Meningococcal bacteria can infect the spinal cord and brain, causing meningitis that can be fatal. Meningococcal disease can also lead to permanent and disabling medical problems. 

Geography - Segment Analysis
North America dominated the meningococcal conjugate vaccine market in 2019 with a share of more than 36.5%, followed by Asia Pacific owing to rising incidences of meningitis and supportive government initiatives and growing efforts of healthcare organizations to curb meningococcal disease .Owing to the rising population, the meningococcal disease is also increasing. Improving healthcare infrastructure, development of quality vaccines at an affordable price and growing awareness about meningococcal vaccination & associated immunization is boosting the growth of meningococcal conjugate vaccine market in the North America region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to development of combination vaccines and government regulations.

Drivers – Meningococcal Conjugate Vaccine Market
  • Rising government awareness programmes and increasing government interventions
Rising  public health awareness initiatives to help prevent children, teens and adolescents from getting infected by meningococcal disease .With an increasing number of individuals becoming aware about the symptoms and impact of meningococcal meningitis and subsequent treatment options, vaccines are garnering notable traction, especially from the worst-hit regions. High rate of mortality and long term neurological defects among infants and young children has been creating an increased demand for promising vaccines. Growing use of meningococcal vaccines for immunization of special risk groups, including travelers or military personnel and for recommended but not reimbursed immunization is fueling gains in the market.  
  • Low manufacturing cost and increasing healthcare spending  
Low manufacturing cost and increasing healthcare spending is boosting the growth of the meningococcal conjugate vaccine. Growing investments by manufacturers and governments to cope with pandemic meningitis and rapidly growing consumption of meningococcal vaccines bolstered by immunization alliances and mass vaccination campaigns among others is increasing the growth of the vaccine. Presence of various government awareness programs, increasing government interventions in refining healthcare infrastructure and incorporation of security guidelines pertaining to meningococcal vaccines are estimated to increase the demand of meningococcal conjugate vaccine.

Challenges – Meningococcal Conjugate Vaccine Market
  • Lack of awareness of the harmful effect of meningitis on toddlers and young children
Some of the factors that can impede the growth of the meningococcal conjugate vaccine   market are lack of awareness of the harmful effect of meningitis on toddlers and young children and also implementing meningococcal immunization programs with adequate vaccine coverage has been effective in decreasing the burden of disease. However, achieving similar results in developing countries.

Meningococcal Conjugate Vaccine Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the meningococcal conjugate vaccine   market. In 2019, meningococcal conjugate vaccine Market share is consolidated by the top ten players present in the market. Meningococcal conjugate vaccine  top 10 companies are Baxter International Inc , Biomed Pvt Ltd , Glaxosmithkline Plc ,  International Medical Corporation ,  Merck Co , Inc ,  Novartis Ag , Pfizer Inc  and Sanofi Pasteur among others.

Acquisitions/Product Launches
  • In December 2019, Baxter International Inc acquires Seprafilm.
  • In September 2019,Baxter International Inc acquires Cheetah Medical.
  • In March 2020,International Medical Corporation acquires Chongqing Guanzan Technology.
1. Meningococcal Conjugate Vaccine Market - Overview
    1.1 Definitions and Scope
2. Meningococcal Conjugate Vaccine Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Composition
    2.3 Key trends by End User
    2.4 Key trends by Geography
3. Meningococcal Conjugate Vaccine Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Meningococcal Conjugate Vaccine Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Meningococcal Conjugate Vaccine Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Meningococcal Conjugate Vaccine Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Meningococcal Conjugate Vaccine Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Meningococcal Conjugate Vaccine Market – By Composition (Market Size –$Million/$Billion)
    8.1 Mono Vaccine
    8.2 Combination Vaccine
9. Meningococcal Conjugate Vaccine Market – By Brand (Market Size –$Million/$Billion)
    9.1 Menactra
    9.2 Menveo
    9.3 Neisvac-C
    9.4 Nimenrix
10. Meningococcal Conjugate Vaccine Market – By End User (Market Size –$Million/$Billion)
    10.1 Child
    10.2 Preteen or Teen
    10.3 Adult
11. Meningococcal Conjugate Vaccine Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia
        11.3.6 New Zealand
        11.3.7 Rest of APAC
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Meningococcal Conjugate Vaccine Market - Entropy
13. Meningococcal Conjugate Vaccine Market – Industry/Segment Competition Landscape   (Premium) 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Meningococcal Conjugate Vaccine Market – Key Company List by Country Premium (Premium)
15. Meningococcal Conjugate Vaccine Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
1.1 Mono Vaccine Market 2019-2024 ($M) - Global Industry Research
1.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
1.2 Combination Vaccine Market 2019-2024 ($M) - Global Industry Research
2.Global Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
2.1 Menactra Market 2019-2024 ($M) - Global Industry Research
2.2 Menveo Market 2019-2024 ($M) - Global Industry Research
2.3 Neisvac-C Market 2019-2024 ($M) - Global Industry Research
2.4 Nimenrix Market 2019-2024 ($M) - Global Industry Research
3.Global Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
3.1 Child Market 2019-2024 ($M) - Global Industry Research
3.2 Preteen Or Teen Market 2019-2024 ($M) - Global Industry Research
3.3 Adult Market 2019-2024 ($M) - Global Industry Research
4.Global Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 (Volume/Units)
4.1 Mono Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
4.1.1 Key Growth Factor And Opportunity Market 2019-2024 (Volume/Units)
4.2 Combination Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
5.Global Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 (Volume/Units)
5.1 Menactra Market 2019-2024 (Volume/Units) - Global Industry Research
5.2 Menveo Market 2019-2024 (Volume/Units) - Global Industry Research
5.3 Neisvac-C Market 2019-2024 (Volume/Units) - Global Industry Research
5.4 Nimenrix Market 2019-2024 (Volume/Units) - Global Industry Research
6.Global Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 (Volume/Units)
6.1 Child Market 2019-2024 (Volume/Units) - Global Industry Research
6.2 Preteen Or Teen Market 2019-2024 (Volume/Units) - Global Industry Research
6.3 Adult Market 2019-2024 (Volume/Units) - Global Industry Research
7.North America Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
7.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
7.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
7.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
8.North America Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
8.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
8.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
8.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
8.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
9.North America Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
9.1 Child Market 2019-2024 ($M) - Regional Industry Research
9.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
9.3 Adult Market 2019-2024 ($M) - Regional Industry Research
10.South America Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
10.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
10.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
10.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
11.South America Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
11.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
11.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
11.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
11.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
12.South America Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
12.1 Child Market 2019-2024 ($M) - Regional Industry Research
12.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
12.3 Adult Market 2019-2024 ($M) - Regional Industry Research
13.Europe Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
13.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
13.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
13.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
14.Europe Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
14.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
14.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
14.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
14.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
15.Europe Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
15.1 Child Market 2019-2024 ($M) - Regional Industry Research
15.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
15.3 Adult Market 2019-2024 ($M) - Regional Industry Research
16.APAC Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
16.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
16.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
16.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
17.APAC Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
17.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
17.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
17.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
17.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
18.APAC Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
18.1 Child Market 2019-2024 ($M) - Regional Industry Research
18.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
18.3 Adult Market 2019-2024 ($M) - Regional Industry Research
19.MENA Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
19.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
19.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
19.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
20.MENA Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
20.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
20.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
20.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
20.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
21.MENA Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
21.1 Child Market 2019-2024 ($M) - Regional Industry Research
21.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
21.3 Adult Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
2.Canada Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
3.Mexico Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
4.Brazil Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
5.Argentina Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
6.Peru Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
7.Colombia Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
8.Chile Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
9.Rest of South America Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
10.UK Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
11.Germany Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
12.France Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
13.Italy Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
14.Spain Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
16.China Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
17.India Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
18.Japan Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
19.South Korea Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
20.South Africa Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
21.North America Meningococcal Conjugate Vaccine By Application
22.South America Meningococcal Conjugate Vaccine By Application
23.Europe Meningococcal Conjugate Vaccine By Application
24.APAC Meningococcal Conjugate Vaccine By Application
25.MENA Meningococcal Conjugate Vaccine By Application
26.Sanofi Pasteur, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Hualan Biological Engineering Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Jn International Medical Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Baxter International Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Serum Institute Of Pvt Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Biomed Pvt Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Novartis Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)